Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals Llc (ACXP)
:ACXP
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
39Underperform
Positive Factors
Clinical Trials
Ibezapolstat's efficacy was impressive in two Phase 2 trials, demonstrating a pooled clinical cure rate of 96%.
Regulatory Approval
Positive regulatory guidance from EU regulators for Phase 3 has been received.
Safety Profile
Ibezapolstat was safe and well-tolerated, with no drug-related withdrawals or serious adverse events occurring.
Negative Factors
Funding Challenges
There needs to be a substantial capital raise and/or other funding resources to initiate a Phase 3 program.
Market Valuation
A combination of macro- and micro- factors have contributed to significant pullbacks in valuations, including ACXP shares which are at an all-time low.
Trial Risks
Risks to the investment thesis and target price include failure or equivocal data in the Phase 3 trials of ibezapolstat.
Acurx Pharmaceuticals (ACXP) vs. S&P 500 (SPY)
Market Cap
$9.24M
Dividend YieldN/A
Average Volume (3M)136.05K
Price to Earnings (P/E)―
Beta (1Y)0.48
Revenue GrowthN/A
EPS Growth23.65%
CountryUS
Employees4
SectorHealthcare
Sector Strength58
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding22,397,510
10 Day Avg. Volume113,445
30 Day Avg. Volume136,054
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.17Price Target Upside1404.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Acurx Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
How the Company Makes MoneyAcurx Pharmaceuticals makes money primarily through the development and commercialization of its proprietary antibiotic compounds. As a clinical-stage company, its revenue model includes potential future sales of its lead product candidate, ibezapolstat, once it successfully completes clinical trials and receives regulatory approval. Additionally, Acurx may secure revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies for the development and commercialization of its pipeline products. These partnerships could involve upfront payments, milestone payments, and royalties on sales. The company's earnings are also influenced by research grants and funding from governmental or non-governmental organizations interested in combating antibiotic-resistant infections.
Acurx Pharmaceuticals Financial Statement Overview
Summary
Acurx Pharmaceuticals exhibits typical early-stage biotech financials with zero revenue and consistent net losses due to focused R&D efforts. The lack of debt is positive, reflecting conservative management, but the ongoing cash outflows and equity erosion pose significant risks.Income Statement
Acurx Pharmaceuticals has consistently reported zero revenue over the years, indicating that it might still be in the development phase typical for many biotech companies. The company has incurred significant net losses, which is expected given the lack of revenue and high costs associated with R&D in this industry. However, the absence of revenue sources is a key concern.10
Very Negative
Balance Sheet
The company's balance sheet shows no debt, which indicates conservative financial management and lowers financial risk. However, the low equity ratio and consistent equity erosion due to net losses are concerning. The company has managed to maintain a positive equity position, though it has decreased over the years.35
Negative
Cash Flow
Acurx Pharmaceuticals is experiencing negative operating cash flows due to ongoing net losses, common for biotech firms without a marketable product yet. However, they have been able to secure financing to mitigate cash outflows, which is crucial for their operations. The lack of free cash flow growth is a significant downside.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | EBIT |
| 0.00 | -14.58M | -12.09M | -12.88M | -4.60M | EBITDA |
| 0.00 | 0.00 | -12.09M | 0.00 | -4.60M | Net Income Common Stockholders |
| -14.10B | -14.58M | -12.09M | -12.68M | -4.60M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 3.71B | 7.47M | 9.11M | 12.96M | 3.18M | Total Assets |
| 3.86B | 7.71M | 9.38M | 13.25M | 3.22M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 66.50K | Net Debt |
| -3.71B | -7.47M | -9.11M | -12.96M | -3.11M | Total Liabilities |
| 3.24B | 3.04M | 2.06M | 843.91K | 522.43K | Stockholders Equity |
| 615.12M | 4.67M | 7.32M | 12.41M | 2.70M |
| Cash Flow | Free Cash Flow | |||
| -10.38B | -9.80M | -7.54M | -5.01M | -3.35M | Operating Cash Flow |
| -10.38B | -9.80M | -7.54M | -5.01M | -3.35M | Investing Cash Flow |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Financing Cash Flow |
| 6.62B | 8.16M | 3.70M | 14.80M | 4.04M |
Acurx Pharmaceuticals Technical Analysis
Neutral
0.41
Price Trends
0.46
Negative
0.63
Negative
1.28
Negative
Market Momentum
>-0.01
Negative
49.91
Neutral
67.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Neutral. The current price of 0.41 is above the 20-day moving average (MA) of 0.38, below the 50-day MA of 0.46, and below the 200-day MA of 1.28, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 49.91 is Neutral, neither overbought nor oversold. The STOCH value of 67.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 54 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
ACXP
Acurx Pharmaceuticals
0.41
-1.67
-80.29%
NURO
Neurometrix
4.58
0.18
4.09%
ERNA
Eterna Therapeutics
0.20
-1.56
-88.64%
PMCB
PharmaCyte Biotech
1.21
-0.94
-43.72%
LYRA
Lyra Therapeutics
0.11
-0.41
-78.85%
OCEA
Ocean Biomedical
0.01
-1.39
-99.29%
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:Mar 18, 2025
(Q4-2024)
| % Change Since: -12.77%|
Next Earnings Date:May 08, 2025
Earnings Call Sentiment Positive
The earnings call presents a generally positive outlook for Acurx Pharmaceuticals, highlighted by significant clinical advancements and regulatory support for its lead candidate, ibezapolstat. Despite financial challenges and the need for additional funding, the company has made meaningful progress in reducing its losses and securing a new patent. Management remains confident in addressing potential NASDAQ listing concerns.Q4-2024 Updates
Positive Updates
Advancement to Phase 3 Trials
Acurx is finalizing preparation to advance ibezapolstat into international Phase 3 clinical trials for treating C. difficile infection, with the potential for regulatory approval in both the US and EU.
Positive Phase 2b Clinical Results
Ibezapolstat demonstrated a 100% clinical cure rate in the Phase 2 program, with no infection recurrence in patients followed for three months post-treatment.
Regulatory Support from FDA and EMA
Received positive regulatory guidance from both the FDA and EMA, aligning on the Phase 3 program's clinical, non-clinical, and manufacturing aspects.
New Patent in Japan
Granted a new patent for DNA polymerase IIIC inhibitors, supporting ongoing development of ACX-375C, with potential applications against MRSA, VRE, and Anthrax.
Financial Improvements
Net loss decreased to $2.8 million in Q4 2024 from $5.1 million in Q4 2023, with significant reductions in research and development and administrative expenses.
Negative Updates
Decreased Cash Position
Cash decreased from $7.5 million at the end of 2023 to $3.7 million at the end of 2024, reflecting financial challenges.
Dependence on External Funding
Phase 3 trial commencement is contingent on securing additional funding, with ongoing efforts to secure partnerships and government grants.
NASDAQ Listing Risk
Concerns about maintaining NASDAQ listing due to current share price, though management is confident in addressing this issue.
Company Guidance
In the recent call, Acurx Pharmaceuticals discussed several key metrics and updates relevant to their fiscal year 2024 performance and future plans. The company reported a net loss of $2.8 million for the fourth quarter of 2024, a decrease from the $5.1 million loss in the same period of 2023. For the full year, the net loss was $14.1 million, a slight improvement from the $14.6 million loss in 2023. Cash reserves at the end of 2024 were $3.7 million, down from $7.5 million at the end of 2023. Research and development expenses decreased to $0.8 million for the last quarter of 2024, primarily due to reduced consulting costs, while general and administrative expenses also fell to $2 million for the same period. The company is poised to advance its lead antibiotic candidate, ibezapolstat, into international Phase 3 trials, with regulatory alignment from both the FDA and EMA. Acurx secured $2.5 million from a direct offering in January 2025 and an additional $1.1 million in a March 2025 offering, underscoring its ongoing efforts to fund its clinical programs.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.